Sesen Bio to Present at the Canaccord Genuity 38th Annual Growth Conference

Sesen Bio, Inc. SESN, a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, today announced that company management will present a corporate overview at the Canaccord Genuity 38^th Annual Growth Conference on Thursday, Aug. 9, 2018 at 1:30 p.m. ET in Boston.

A live webcast of the company's presentation will be accessible from the Investors & Media section of Sesen Bio's website, www.sesenbio.com. An archived replay of the webcast will be available on the company's website for 90 days after the conference.

About Sesen Bio

Sesen Bio, Inc. is a late-stage clinical company advancing next-generation antibody-drug conjugate therapies for the treatment of cancer based on the company's Targeted Protein Therapeutics platform. The company's lead program, Vicinium™, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA Trial, for the treatment of high-grade non-muscle invasive bladder cancer. Vicinium incorporates a tumor-targeting antibody fragment and a protein cytotoxic payload into a single protein molecule designed to selectively and effectively kill cancer cells while sparing healthy cells. For more information, please visit the company's website at www.sesenbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180802005160/en/